Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01993433 | A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis | PHASE2 | COMPLETED | 23 | — | — | Oct 1, 2013 | Mar 1, 2014 | Jul 20, 2021 | 2 | Canada |
| Arm | Type | Description |
|---|---|---|
| DRM02 | EXPERIMENTAL | DRM02 Topical Gel, 0.25% |
| Vehicle | PLACEBO_COMPARATOR | DRM02 Topical Gel, Vehicle |
| Name | Type | Description |
|---|---|---|
| DRM02 | DRUG | - |
| Vehicle | OTHER | - |
Inclusion Criteria: * Male or female 18 to 70 years of age. * Plaque-type psoriasis with two lesions of similar size and have an identical score of at least 6 but no more than 8 on the sum of the individual components of the Severity of Psoriasis Area Severity Index (PASI) at the Target Lesion scal...